Gynecologists generally have the opportunity to perform in-office procedures for three indications: abnormal uterine bleeding, permanent contraception and uterine fibroids. Hologic Inc., had supplied its 460 medical device reps in the US – the largest force in women's health – with the tools to perform two of these procedures, NovaSure for women experiencing heavy bleeding, and an implantable contraception product called Adiana, both products acquired when it bought Cytyc Corp. in 2007. [See Deal] But Hologic reps couldn't offer the third piece of the puzzle, an in-office treatment for fibroids, a gap which, until now, hasn't been filled by any product on the market.
Hologic is filling in the missing piece with the acquisition of privately held Interlace Medical Inc., a start-up developing MyoSure a minimally invasive resection device for submucosal fibroids.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?